These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
436 related articles for article (PubMed ID: 38679698)
1. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. Shen KY; Zhu Y; Xie SZ; Qin LX J Hematol Oncol; 2024 Apr; 17(1):25. PubMed ID: 38679698 [TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
3. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Oura K; Morishita A; Tani J; Masaki T Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550 [TBL] [Abstract][Full Text] [Related]
4. The State of Immunotherapy in Hepatobiliary Cancers. Ilyas FZ; Beane JD; Pawlik TM Cells; 2021 Aug; 10(8):. PubMed ID: 34440865 [TBL] [Abstract][Full Text] [Related]
5. Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies. Zarlashat Y; Mushtaq H; Pham L; Abbas W; Sato K Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999940 [TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W Front Immunol; 2020; 11():1037. PubMed ID: 32547550 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X Front Immunol; 2021; 12():765101. PubMed ID: 34675942 [TBL] [Abstract][Full Text] [Related]
8. The current status and future of targeted-immune combination for hepatocellular carcinoma. Hao L; Li S; Ye F; Wang H; Zhong Y; Zhang X; Hu X; Huang X Front Immunol; 2024; 15():1418965. PubMed ID: 39161764 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for hepatocellular carcinoma. Wang X; Lu J Chin Med J (Engl); 2024 Aug; 137(15):1765-1776. PubMed ID: 38855876 [TBL] [Abstract][Full Text] [Related]
10. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. Fu Y; Liu S; Zeng S; Shen H J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650 [TBL] [Abstract][Full Text] [Related]
11. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma. Caraballo Galva LD; Cai L; Shao Y; He Y J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500 [TBL] [Abstract][Full Text] [Related]
12. Recent developments with immunotherapy for hepatocellular carcinoma. Waidmann O Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens? Repáraz D; Aparicio B; Llopiz D; Hervás-Stubbs S; Sarobe P Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216137 [TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges. Rizzo A; Brunetti O; Brandi G Int J Mol Sci; 2024 Oct; 25(20):. PubMed ID: 39456872 [TBL] [Abstract][Full Text] [Related]
15. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977 [TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Giraud J; Chalopin D; Blanc JF; Saleh M Front Immunol; 2021; 12():655697. PubMed ID: 33815418 [TBL] [Abstract][Full Text] [Related]
17. Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance. Fu Y; Guo X; Sun L; Cui T; Wu C; Wang J; Liu Y; Liu L Elife; 2024 Aug; 13():. PubMed ID: 39146202 [TBL] [Abstract][Full Text] [Related]
18. Immune-based therapies for hepatocellular carcinoma. Pinato DJ; Guerra N; Fessas P; Murphy R; Mineo T; Mauri FA; Mukherjee SK; Thursz M; Wong CN; Sharma R; Rimassa L Oncogene; 2020 Apr; 39(18):3620-3637. PubMed ID: 32157213 [TBL] [Abstract][Full Text] [Related]
19. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T Front Immunol; 2021; 12():733530. PubMed ID: 34659220 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for hepatocellular carcinoma: Current and future. Johnston MP; Khakoo SI World J Gastroenterol; 2019 Jun; 25(24):2977-2989. PubMed ID: 31293335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]